Abstract
The natural products teleocidins, phorbol esters, asplysiatoxin, ingenol esters, and bryostatins are all potent protein kinase C (PKC) activators. The fact that they act at the same site of PKC implied that these structurally diverse molecules might contain the common structural elements. Several pharmacophores for these compounds have been proposed based on the molecular modeling studied and experimental results. In order to prove these hypotheses various simplified analogues of these compounds are designed, synthesized, and evaluated as new PKC activators. Some of the simplified analogues demonstrated much high potency to activate PKC, which not only gives some insights how these PKC activators bind with PKC, but also provides the new leads to develop the therapeutic tools to treat the diseases related by PKC.
Current Medicinal Chemistry
Title: Recent Advances in the Discovery of Protein Kinase C Modulators Based on the Structures of Natural Protein Kinase C Activators
Volume: 8 Issue: 2
Author(s): Dawei Ma
Affiliation:
Abstract: The natural products teleocidins, phorbol esters, asplysiatoxin, ingenol esters, and bryostatins are all potent protein kinase C (PKC) activators. The fact that they act at the same site of PKC implied that these structurally diverse molecules might contain the common structural elements. Several pharmacophores for these compounds have been proposed based on the molecular modeling studied and experimental results. In order to prove these hypotheses various simplified analogues of these compounds are designed, synthesized, and evaluated as new PKC activators. Some of the simplified analogues demonstrated much high potency to activate PKC, which not only gives some insights how these PKC activators bind with PKC, but also provides the new leads to develop the therapeutic tools to treat the diseases related by PKC.
Export Options
About this article
Cite this article as:
Ma Dawei, Recent Advances in the Discovery of Protein Kinase C Modulators Based on the Structures of Natural Protein Kinase C Activators, Current Medicinal Chemistry 2001; 8 (2) . https://dx.doi.org/10.2174/0929867013373868
DOI https://dx.doi.org/10.2174/0929867013373868 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptide-Receptor Ligands and Multivalent Approach
Anti-Cancer Agents in Medicinal Chemistry Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges
Current Pharmaceutical Design Aptamers: Potential Applications to Pancreatic Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry New Tubulin Polymerization Inhibitor Derived from Thalidomide: Implications for Anti-Myeloma Therapy
Current Medicinal Chemistry Vincristine-Induced Seizure Potentiated by Itraconazole Following RCHOP Chemotherapy for Diffuse Large B-Cell Lymphoma
Current Drug Safety Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Current Cardiology Reviews Drug Delivery Systems Based on Polymeric Micelles and Ultrasound: A Review
Current Pharmaceutical Design Electrochemical Indicators for DNA Electroanalysis
Current Analytical Chemistry Anticancer Alkylphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects
Current Pharmaceutical Design The Putative Use of Lithium in Alzheimer’s Disease
Current Alzheimer Research WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide
Anti-Cancer Agents in Medicinal Chemistry Erythropoietin in Cancer: An Update
Current Molecular Medicine MicroRNA-21 as a Novel Therapeutic Target
Current Cancer Therapy Reviews Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Current Cancer Drug Targets An Overview of Notch Signaling in Adult Tissue Renewal and Maintenance
Current Alzheimer Research NF-κB Activation by FcεRI-Mediated Signal Transduction
Current Immunology Reviews (Discontinued) Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry The Linkage Between Inflammation and Immune Tolerance: Interfering with Inflammation in Cancer
Current Cancer Drug Targets Postoperative Care of the Transplanted Patient
Current Cardiology Reviews